Skip to content

The effect of albuterol spray on hypoxia and bronchospasm in patients with chronic obstructive pulmonary disease (COPD)

The effect of albuterol spray-on hypoxia and bronchospasm in patients with chronic obstructive pulmonary disease (COPD) under general anesthesia

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170108031818N1
Enrollment
120
Registered
2021-11-29
Start date
2021-11-06
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pulmonary obstruction(COPD). J44. 9

Interventions

Intervention group: The patient receives 2 puffs of albuterol spray (2.5 micrograms per puff) 20 minutes before anesthesia.

Sponsors

Gorgan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to No maximum

Inclusion criteria

Inclusion criteria: The patient is a smoker ASA is class 1 and 2 The patient has a history of COPD

Exclusion criteria

Exclusion criteria: The patient develops bronchospasm during the operation The surgery lasted more than 3 hours Pulmonary artery pressure is greater than 25 mm Hg Changes in blood pressure, heart rate and drop in severity by 20% of baseline

Design outcomes

Primary

MeasureTime frame
Wheezing. Timepoint: once. After intubation of the endotracheal tube. Method of measurement: Using a medical earphone, the patient's lungs can be heard.;Frequent coughing. Timepoint: 2 times - before anesthesia and after ecstasy. Method of measurement: By observing the appearance of the patient.;Bronchospasm. Timepoint: 1 time. After anesthesia. Method of measurement: If the patient is intubated, bronchospasm is suspected by the anesthesia ventilator storage bag if the storage bag tightens and is considered positive and recorded.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmahrokh maddah

Gorgan University of Medical Sciences

mehravar10261@goums.ac.ir+98 17 3217 7419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026